My 3 market-beating share picks for 2017

Blackmores Limited (ASX:BKL) is one of three shares which I believe will outperform the S&P/ASX 200 (Index:^AXJO) (ASX:XJO) in 2017. Here's why…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

After a very slow start the benchmark S&P/ASX 200 (Index: ^AXJO) (ASX: XJO) looks set to finish the year with a gain of around 6% thanks largely to its strong run since the U.S. election.

Because of this strong finish the three shares below look very unlikely to beat the market this year. But in 2017 I believe it will be a different story. So much so I'm tipping them to bounce back and beat the market next year. Here's why:

Blackmores Limited (ASX: BKL)

This health supplements company has fallen from grace this year and now finds itself trading 53% lower than its 52-week high. A weak first quarter due to destocking left many investors nervous, especially considering the plight of Bellamy's Australia Ltd (ASX: BAL). But management is confident that its second-half performance will be much stronger. At the current price and offering a generous dividend yield, I believe Blackmores will move significantly higher in 2017.

Capilano Honey Ltd (ASX: CZZ)

Year to date the share price of this leading honey producer has fallen around 25%. As a result its shares can be snapped up for just under 15x trailing earnings, which I believe puts them in bargain territory. Following a strong FY 2016 which saw net profit after tax jump 20.9% to $9.5 million, I believe the company is positioned for further growth in FY 2017. The launch of its health and wellness Beeotic range and the commencement of distribution into China through the pharmacy channel should all be a boost.

Mayne Pharma Group Ltd (ASX: MYX)

Although this growing pharmaceutical company has rallied strongly this week, it is still down slightly year to date. This decline is the result of Mayne Pharma being named in a U.S. lawsuit for alleged price-fixing of generic drugs. I think the sell-off has been a massive overreaction, especially considering management has constantly reiterated that any penalties imposed will not be material. With such a lucrative pipeline of generic drugs due for release over the next 12 months, I think Mayne Pharma has a great chance of beating the market next year.

Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia owns shares of Bellamy's Australia and Capilano Honey Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »